Akebia Therapeutics (AKBA) Inventory (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Inventory data on file, last reported at $13.0 million in Q1 2026.

• On a quarterly basis, Inventory fell 34.14% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $13.0 million, a 34.14% decrease from a year earlier, with the FY2025 full-year figure at $15.6 million, down 3.9% from the prior year.
• Inventory for Q1 2026 stood at $13.0 million, down from $15.6 million in the prior quarter.
• Over the last five years, Inventory for AKBA reached as high as $45.2 million in Q3 2022 and fell as low as $13.0 million in Q1 2026.
• Historically, Inventory has averaged $23.1 million across 5 years, with a median of $20.4 million in 2023.
• Across the five-year window, Inventory soared 34.3% in 2022 and sank 59.24% in 2023, its largest moves.
• Year by year, Inventory stood at $21.6 million in 2022, then declined by 27.25% to $15.7 million in 2023, then gained by 3.52% to $16.2 million in 2024, then slipped by 3.9% to $15.6 million in 2025, then fell by 16.75% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Inventory figures were $13.0 million in Q1 2026, $15.6 million in Q4 2025, and $18.6 million in Q3 2025.